SPOTLIGHT -
FDA Grants Accelerated Approval to Tucatinib Plus Trastuzumab for Advanced HER2+ Metastatic CRC
The FDA based its accelerated approval of tucatinib and trastuzumab combination therapy for HER2-positive metastatic colorectal cancer on results from the phase 2 MOUNTAINEER trial.
FDA Accelerated Approval of Tucatinib/Trastuzumab for HER2+ Metastatic CRC May ‘Improve Access’ to Treatment
An expert from the Duke University School of Medicine describes how the FDA approval of tucatinib plus trastuzumab in HER2-positive metastatic colorectal cancer will improve access to treatment.
